Navigation Links
ViroPharma Provides Update on Vancocin(R)
Date:1/8/2008

view in the Center. The stated mission of OPS is to ensure that high quality, safe and effective, new and generic drugs are available to the public by applying sound scientific and regulatory standards. The OPS oversees the activities of several FDA offices, including the OGD.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development of products that address serious diseases treated by physician specialists and in hospital settings. Vancocin(R) is approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com.

Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties, including the Company's plans to continue to oppose vigorously any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in ViroPharma's Vancocin related submissions or that ViroPharma's efforts to oppose the OGD's March 2006 recommendation to determine bioequivalence to Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma Augments Senior Management
2. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
3. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
4. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
5. ViroPharma to Present at the UBS Global Life Sciences Conference
6. ViroPharma to Present at the Maxim Group First Annual Growth Conference
7. HearAtLast Holdings, Inc. Provides Shareholder Update
8. Mayo Clinic Proceedings provides forum for debate about capital punishment
9. Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits
10. Akela Pharma provides corporate update
11. Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... A report out just last ... best option for avoiding cardiovascular disease is exercise and ... the single most powerful predictor of death and survival, ... and family history of premature death -- a finding ... lung fitness. , The Importance of Cardiovascular Screening , ...
(Date:5/23/2015)... On Wednesday, May 20, 2015, CareFirst ... been the target of a sophisticated cyberattack,” and that ... ongoing Information Technology (IT) security efforts in the wake ... most notable attack on health insurers was reported in ... second largest health insurer, revealed that they had suffered ...
(Date:5/23/2015)... 2015 Add High-Quality prismatic refractions into footage ... , It's as simple as dragging and dropping footage into ... for full effect. , Including over 80 stunning flares, ... sensors making this the ultimate bundle for adding prismatic refractions ... this package are movie files designed for Final Cut Pro ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of ... on Friday, May 29, 2015 at 11 a.m., followed by ... new medical center, set to officially open on June 1, ... 84043. , “The opening of Mountain Point Medical Center ... County community,” said Kent Loosle, CEO of Mountain Point Medical ...
(Date:5/22/2015)... 22, 2015 Combination therapy, or ... for chronic obstructive pulmonary disorder (COPD) as the ... AstraZeneca plc as well as Germany’s Boehringer Ingelheim ... position. But will market payers, clinicians and patients ... products to completely new ones? , In spite ...
Breaking Medicine News(10 mins):Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... costs by an average 1% over two years ... wellness initiatives including smoker surcharges.TROY, Mich., May 18 ... brokerage/consulting firm, today released the results of its ... survey compares health benefits and trends for the ...
... Myeloma Research Foundation (MMRF) announced today a collaboration with ... uncover the molecular changes underlying multiple myeloma by whole ... provide both patient samples for analysis as well as ... will be put in the public domain. , "We ...
... abreast of the most important osteoporosis-related research? Progress ... the International Osteoporosis Foundation (IOF) on www.iofbonehealth.org/pio ... preceding three to four months. The journal is edited ... of the University of Melbourne, Australia. , ...
... SAINT PETERSBURG, Fla. , May 18 ... competitive $1.28 billion Picture Archiving Communications Systems (PACS) ... Sullivan,s "Technology Leadership Award for Cardiovascular PACS" (CVPACS), ... by KLAS, Thinking Systems Corporation develops and markets ...
... Health Systems, Inc. (NYSE Amex: ADK ), an ... reported financial results for its first quarter of 2009. ... as compared to $5,992,542 for the same quarter in 2008, ... to improved occupancy at its assisted living communities, an increase ...
... California to volunteer in their communities INDIANAPOLIS, May ... blanket communities in the U.S. and across the globe as ... and energy to improve the health and well-being of their ... of Service.Last year, more than 20,000 Lilly employees from more ...
Cached Medicine News:Health News:McGraw Wentworth Mid-Market Group Benefits Survey Shows Health Care Costs Increasing at 6-Year Low of 5% 2Health News:McGraw Wentworth Mid-Market Group Benefits Survey Shows Health Care Costs Increasing at 6-Year Low of 5% 3Health News:MMRF and the Broad Institute to perform whole genome sequencing of multiple myeloma samples 2Health News:Thinking Systems to Showcase the Company's Upgraded ThinkingPACS(TM) and ThinkingRIS(TM) Solutions 2Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 2Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 3Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 4Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 5Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 6Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 7Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 8Health News:Lilly to Celebrate Second Annual Global Day of Service May 20 2Health News:Lilly to Celebrate Second Annual Global Day of Service May 20 3
(Date:5/22/2015)...  The Mesothelioma Victims Center is incredibly passionate ... the best possible compensation, and they are also extremely ... cancer caused by exposure to asbestos or their ... treatment options such as a recent possible medical breakthrough. ... Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)...   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or ... today announced that its CGuard TM Embolic Prevention System ... Piotr Musialek , at the EuroPCR conference ... . PARADIGM, an investigator-initiated P rospective evaluation ... D revascularization I n symptomatic and increased-risk asymptomatic ...
(Date:5/22/2015)... , May 22, 2015  In a sweeping ... the U.S., T1D Exchange researchers conclude that ... type 1 diabetes across all age groups, but especially ... most up-to-date picture of diabetes treatment, underscoring the need ... and technologies that can help type 1 patients achieve ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... Oct. 31, 2011 Menicon Holdings BV and Eye ... a France-based independent ophthalmic group, announced on October 31 ... to market the SOLO-care (R) contact lens solutions range ... Canada. The agreement will enable Menicon to ...
... 28, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... States District Court for the District of Massachusetts ... request for a preliminary injunction preventing Watson and ... Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis, ...
Cached Medicine Technology:Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX® 2Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX® 3
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: